#Los Gatos #hydrogel technology #Tulavi Therapeutics #Ramond W. Cohen

Tulavi Therapeutics Expands Leadership Team with Raymond W. Cohen

Tulavi Therapeutics, Inc., headquartered in Los Gatos, California, is set to make waves in the medical device landscape with its innovative approach to peripheral nerve surgery. On June 18, 2025, the company announced the appointment of Raymond W. Cohen as Vice Chairman of its Board of Directors. This strategic move signals a pivotal moment in Tulavi's growth, as they aim to amplify the impact of their Adaptive Hydrogel Technology.

Raymond W. Cohen, a seasoned executive in the medical technology field, brings with him an exemplary record of transforming companies in this niche. Having co-founded the Nasdaq-listed company Axonics, Inc., Cohen played a crucial role in its public listing in October 2018. Under his leadership, Axonics was recognized by Deloitte’s Technology Fast 500™ and Financial Times as one of the fastest-growing companies in the Americas for two consecutive years (2021 & 2022). Following the successful acquisition by Boston Scientific Corporation (BSX), Cohen took the opportunity to pivot his career towards new ventures, where he now focuses on supporting innovative medical device companies.

As Tulavi's new Vice Chairman, Cohen’s expertise in hydrogels and neurology is invaluable. Dr. Josh Vose, CEO of Tulavi Therapeutics, expressed enthusiasm regarding Cohen's appointment, stating, “Ray brings to our board an exceptional track record of building and scaling innovative medical device companies, combined with a deep understanding of hydrogels, neurology, and device markets.